COCP Cocrystal Pharma Inc
Price (delayed)
$1.31
Market cap
$13.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.72
Enterprise value
$5.17M
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses.
Highlights
Cocrystal Pharma's EPS has increased by 8% YoY and by 7% from the previous quarter
Cocrystal Pharma's net income has increased by 6% from the previous quarter and by 2.7% YoY
The company's equity has shrunk by 64% YoY and by 25% QoQ
The company's quick ratio fell by 50% YoY and by 39% QoQ
Key stats
What are the main financial stats of COCP
Market
Valuations
Earnings
Shares outstanding
10.17M
Market cap
$13.33M
Enterprise value
$5.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$17.88M
Net income
-$17.5M
EBIT
-$17.5M
EBITDA
-$17.38M
Free cash flow
-$16.49M
Per share
Balance sheet
Liquidity
EPS
-$1.72
EPS diluted
-$1.72
Free cash flow per share
-$1.62
Book value per share
$0.94
Revenue per share
$0
TBVPS
$1.32
Total assets
$13.46M
Total liabilities
$3.93M
Debt
$1.81M
Equity
$9.52M
Working capital
$9.15M
Debt to equity
0.19
Current ratio
4.77
Quick ratio
4.1
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-90%
Return on equity
-112.6%
Return on invested capital
-565.4%
Return on capital employed
-158.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COCP stock price
How has the Cocrystal Pharma stock price performed over time
Intraday
0%
1 week
6.94%
1 month
-21.12%
1 year
-8.39%
YTD
-35.15%
QTD
-7.75%
Financial performance
How have Cocrystal Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$17.88M
Net income
-$17.5M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 7% from the previous quarter and by 3.7% YoY
Cocrystal Pharma's net income has increased by 6% from the previous quarter and by 2.7% YoY
Growth
What is Cocrystal Pharma's growth rate over time
Valuation
What is Cocrystal Pharma stock price valuation
P/E
N/A
P/B
1.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Cocrystal Pharma's EPS has increased by 8% YoY and by 7% from the previous quarter
The company's equity has shrunk by 64% YoY and by 25% QoQ
The stock's P/B is 27% above its 5-year quarterly average of 1.1
Efficiency
How efficient is Cocrystal Pharma business performance
Cocrystal Pharma's ROE has plunged by 98% YoY and by 19% from the previous quarter
The ROA has plunged by 73% YoY and by 15% from the previous quarter
COCP's return on invested capital is up by 41% year-on-year and by 3.3% since the previous quarter
Dividends
What is COCP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COCP.
Financial health
How did Cocrystal Pharma financials performed over time
The total assets has plunged by 57% YoY and by 17% from the previous quarter
The company's quick ratio fell by 50% YoY and by 39% QoQ
The debt is 81% less than the equity
COCP's debt to equity has soared by 171% YoY and by 27% QoQ
The company's equity has shrunk by 64% YoY and by 25% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.